SEC FORM 4

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Furlow Brenda S.

(Last)

(First)

(Middle)

614 MCKINLEY PL N E

(Street)

MINNEAPOLIS

55413

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
SVP - GENERAL COUNSEL

3. Date of Earliest Transaction (Month/Day/Year)
12/07/2022

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	12/07/2022		M		800	A	$31.2625	26,892	D
Common Stock	12/07/2022		S		800	D	$82.0063	26,092	D
Common Stock	12/08/2022		M		7,450	A	$31.2625	33,542	D
Common Stock	12/08/2022		S		7,450	D	$82.1222⁽¹⁾	26,092	D
Common Stock								5,320	I	By Trust #1
Common Stock								5,320	I	By Trust #2

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to Buy)	$31.2625	12/07/2022		M			800	⁽²⁾	08/09/2024	Common Stock	800	$0	37,212	D
Stock Options (Right to Buy)	$31.2625	12/08/2022		M			7,450	⁽²⁾	08/09/2024	Common Stock	7,450	$0	29,762	D
Stock Options (Right to Buy)	$44.33							⁽²⁾	08/08/2025	Common Stock	66,248		66,248	D
Stock Options (Right to Buy)	$47.6025							⁽²⁾	08/07/2026	Common Stock	39,872		39,872	D
Stock Options (Right to Buy)	$47.6025							⁽³⁾	08/07/2026	Common Stock	53,160		53,160	D
Restricted Stock Units	⁽⁴⁾							⁽⁵⁾	⁽⁵⁾	Common Stock	6,716		6,716	D
Stock Options (Right to Buy)	$66.9675							⁽⁵⁾	08/05/2027	Common Stock	29,968		29,968	D
Stock Options (Right to Buy)	$66.9675							⁽⁶⁾	08/05/2027	Common Stock	39,960		39,960	D
Stock Options (Right to Buy)	$66.9675							⁽⁷⁾	08/05/2027	Common Stock	$33,300		$33,300	D
Stock Options (Right to Buy)	$66.9675							⁽⁸⁾	08/05/2027	Common Stock	33,300		33,300	D
Stock Options (Right to Buy)	$93.11							08/31/2022	03/01/2028	Common Stock	43,988		43,988	D
Restricted Stock Units	⁽⁴⁾							⁽⁹⁾	⁽⁹⁾	Common Stock	4,668		4,668	D
Stock Options (Right to Buy)	$120.455							⁽⁹⁾	08/06/2028	Common Stock	18,240		18,240	D
Stock Options (Right to Buy)	$120.455							⁽¹⁰⁾	08/06/2028	Common Stock	24,320		24,320	D
Stock Options (Right to Buy)	$94.52							⁽¹¹⁾	08/15/2029	Common Stock	24,664		24,664	D
Restricted Stock Units	⁽⁴⁾							⁽¹²⁾	⁽¹²⁾	Common Stock	7,936		7,936	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 82.0000 to 82.4900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. Fully exercisable.

3. Options to purchase13,292 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 13,288 shares vest on each of 8/7/2022 and 8/7/2023.

4. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

5. Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

6. Options to purchase 9,992 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 9,988 shares vest on each of 8/5/2023 and 8/5/2024.

7. Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.

8. Options to purchase 11,100 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.

9. Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

10. Options to purchase 6,080 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025.

11. Options to purchase 6,168 shares vest on each of 8/15/2023 and 8/15/2025 and options to purchase 6,164 shares vest on 8/15/2024 and 8/15/2026.

12. 2,644 shares vest on each of 8/15/2023 and 8/15/2025, and 2,648 shares vest on 8/15/2024.

Remarks:

On November 28, 2022, the Company completed a four-for-one stock split. All common stock amounts and exercise prices in the filing relating to securities acquired prior to November 28, 2022 have been adjusted to reflect the four-for-one stock split.

	/s/ Andrew Nick as Attorney-in-Fact for Brenda S. Furlow pursuant to Power of Attorney previously filed	12/09/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.